|
|||||
|
|
A medical device company is licensing a minimally-invasive technology developed in university labs for detection of Barrett’s esophagus, a condition that often leads to esophageal cancer. . . . → Read More: Univ. Licenses Barrett’s Esophagus Detection Device 
A company is getting underway to develop therapies that extend genome editing to repair genetic disruptions, not just remove them from DNA. . . . → Read More: Genetic Repair Company Starts-Up, Gains $87 Million 
Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil. . . . → Read More: Genentech Gains Microbe Drug Discovery Tech in $1B Deal  Comments are closed  Intellectual property  biomedical, biotechnology, chemistry, entrepreneurs, equity, genomics, investment, licensing, life sciences, pharmaceuticals, physical sciences, university, venture capital Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases. . . . → Read More: Lilly, Cell Implants Start-Up Partner on Diabetes A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies One comment - (Comments are closed) Finance, Intellectual property, Joint ventures/collaborations biomedical, biotechnology, cancer, entrepreneurs, equity, genomics, investment, licensing, life sciences, patent, pharmaceuticals, venture capital A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells Comments are closed Intellectual property, New products biomedical, biotechnology, cancer, engineering, entrepreneurs, genomics, grant, licensing, life sciences, NIH, NSF, patent, pharmaceuticals, university MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies Comments are closed Intellectual property biomedical, biotechnology, cancer, genomics, Israel, licensing, life sciences, mathematics, pharmaceuticals, physical sciences A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments. . . . → Read More: Patent Awarded for Nanoparticle Drug, Cannabis Delivery One comment - (Comments are closed) Intellectual property biomedical, chemistry, engineering, licensing, life sciences, materials science, nanotechnology, patent, pharmaceuticals, physical sciences, USPTO Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer. . . . → Read More: Novartis Licenses Biomaterial for Cancer Immunotherapy One comment - (Comments are closed) Intellectual property, Joint ventures/collaborations biomedical, biotechnology, cancer, clinical trials, engineering, Europe, licensing, materials science, pharmaceuticals, physical sciences, university Drug discovery company Evotec AG is licensing 10 infectious disease R&D programs and their 100 employees from drug maker Sanofi, and opening new labs for this work in Lyon, France. . . . → Read More: Evotec Acquiring Sanofi Infectious Disease Portfolio Comments are closed Hiring/layoffs, Intellectual property biomedical, Europe, licensing, life sciences, pharmaceuticals |
One Blood Test Fits All Diseases A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
|||
|
Copyright © 2018 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
